CD274 and lung cancer: Briefly, mAbs targeting the PD-1/PD-L1 axis has shown tremendous benefit in clinical trials and have been approved as second-line or first-line therapies for an increasing number of carcinomas, including lung cancer, melanoma, lymphoma, among others (7).